(Q46029821)

18 December 2017

title

Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. (English)

1 reference

18 December 2017

1 reference

1 reference

0 references

John Bernardo

8

0 references

Charles M. Heilig

Charles M Heilig

7

0 references

Nesri Padayatchi

Nesri Padayatchi

5

0 references

Richard E Chaisson

19

Richard E Chaisson

1 reference

18 December 2017

15

Dick Menzies

1 reference

18 December 2017

Harriet Mayanja-Kizza

0 references

Jacques Grosset

10

Jacques H Grosset

1 reference

18 December 2017

Eric Nuermberger

16

Eric L Nuermberger

1 reference

18 December 2017

author name string

Susan E Dorman

1

1 reference

18 December 2017

John L Johnson

2

1 reference

18 December 2017

Stefan Goldberg

3

1 reference

18 December 2017

Grace Muzanye

4

1 reference

18 December 2017

Lorna Bozeman

6

1 reference

18 December 2017

Shurjeel Choudhri

9

1 reference

18 December 2017

Elizabeth Guy

11

1 reference

18 December 2017

Priya Guyadeen

12

1 reference

18 December 2017

Maria Corazon Leus

13

1 reference

18 December 2017

Gina Maltas

14

1 reference

18 December 2017

Margarita Villarino

17

1 reference

18 December 2017

Andrew Vernon

18

1 reference

18 December 2017

Tuberculosis Trials Consortium

20

1 reference

18 December 2017

language of work or name

English

0 references

publication date

30 April 2009

1 reference

18 December 2017

American Journal of Respiratory and Critical Care Medicine

published in

1 reference

18 December 2017

volume

180

1 reference

18 December 2017

page(s)

273-280

1 reference

18 December 2017

issue

3

1 reference

18 December 2017

Moxifloxacin-containing Regimen Greatly Reduces Time to Culture Conversion in Murine Tuberculosis

cites work

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200901-0078OC

Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200901-0078OC

Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200901-0078OC

Moxifloxacin (BAY12-8039), a new 8-methoxyquinolone, is active in a mouse model of tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200901-0078OC

The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200901-0078OC

Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200901-0078OC

Safety profile of oral and intravenous moxifloxacin: cumulative data from clinical trials and postmarketing studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200901-0078OC

Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200901-0078OC

Outpatient gatifloxacin therapy and dysglycemia in older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200901-0078OC

American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200901-0078OC

Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200901-0078OC

Effectiveness of once-weekly rifapentine and moxifloxacin regimens against Mycobacterium tuberculosis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200901-0078OC

Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200901-0078OC

Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200901-0078OC

Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200901-0078OC

Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200901-0078OC

Powerful bactericidal activity of sparfloxacin (AT-4140) against Mycobacterium tuberculosis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200901-0078OC

Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200901-0078OC

Weekly moxifloxacin and rifapentine is more active than the denver regimen in murine tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.200901-0078OC

10.1164/RCCM.200901-0078OC

21 January 2018

Identifiers

DOI

1 reference

18 December 2017

release_o4qzl5lbg5fl5aly5xds7gn2x4

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/o4qzl5lbg5fl5aly5xds7gn2x4

mapped directly with Wikidata item

24 November 2022

based on heuristic

PubMed ID

19406981

1 reference

18 December 2017